Evaluation of Atypical Low Energy Fractures in Patients Affected by Multiple Myeloma Treated with Bispohosphonates

Samantha Pozzi(University of Modena and Reggio Emilia), Stefano Sacchi(University of Modena and Reggio Emilia), Giuseppe Caparrotti(Federico II University Hospital), Alessia Bari, Daniela Petrò(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Maria Teresa Donini(Azienda Ospedaliero-Universitaria di Modena), Pellegrino Musto(University of Bari Aldo Moro), Paola Bresciani(Azienda Ospedaliero-Universitaria di Modena), Santo Neri(Azienda Ospedaliera Ospedali Riuniti Papardo Piemonte), Elisa Ferraris(Fondazione Salvatore Maugeri), Luigi Marcheselli(University of Modena and Reggio Emilia), Antônio Palumbo, Luciano Masini(Casa di Cura Villa Garda), Eliana Valentina Liardo(University of Modena and Reggio Emilia), Raffaella Marcheselli
Blood
November 18, 2011
10.1182/blood.v118.21.5134.5134
Cited by 0

Related Papers

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study
|Journal of Clinical Oncology|2007|374
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
|Blood|2012|310
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients
|Blood|2011|268
Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma
|Journal of Clinical Oncology|2010|268